Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Prednisolone Metasulfobenzoate→

Prednisolone Metasulfobenzoate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
3694-41-5
Molecular formula
C28H32O9S
Molecular weight
544.61 g/mol
Drug class
Topical glucocorticoid corticosteroidprednisolone 21-metasulphobenzoate sodium salt
Mechanism of action
A water-soluble ester of prednisolone that releases or delivers the active glucocorticoid locally. Prednisolone activates intracellular glucocorticoid receptors, regulating inflammatory gene transcription and suppressing mucosal inflammatory responses.
Indications / reported uses
  • Rectal foam or rectal solution treatment of distal ulcerative colitis and other corticosteroid-responsive inflammatory conditions of the rectum or distal colon under the specific product label.

Sources: https://www.medicines.org.uk/emc/ingredient/10487 · https://www.medicines.org.uk/emc/product/11245/smpc · https://precision.fda.gov/uniisearch/srs/unii/d345thm53t · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Prednisolone Metasulfobenzoate Environmental Risk Assessment (ERA) (the Prednisolone Metasulfobenzoate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.